Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29869052 | 1.00 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL29441383 | 1.00 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL29869032 | 1.00 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL30259429 | 1.00 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL29608026 | 1.00 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL24621693 | 1.00 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL16172443 | 0.98 | MGLL (0.52) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL19318350 | 0.94 | MGLL (0.49) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL17833093 | 0.94 | MGLL (0.49) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL15148264 | 0.94 | MGLL (0.49) | MGLLCA2CA12CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322958-A1 | Anti-Notch2 Antibodies and Conjugates and Methods of Use | GENENTECH, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11279771-B2 | Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) | NOVO NORDISK A/S (DK) | 2022-03-22 | — | — | US | disclosed |
| EP-3194447-B1 | ANTIBODIES CAPABLE OF BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR (1-161) | NOVO NORDISK AS (DK) | 2021-12-01 | — | — | EP | disclosed |
| US-10717784-B2 | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor | NOVO NORDISK A/S (DK) | 2020-07-21 | — | — | US | disclosed |
| US-20180208675-A1 | ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR | NOVO NORDISK AS (DK) | 2018-07-26 | — | — | US | disclosed |
| US-9896513-B2 | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor | NOVO NORDISK A/S (DK) | 2018-02-20 | — | — | US | disclosed |
| US-20170260289-A1 | ANTIBODIES CAPABLE OF BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR (1-161) | NOVO NORDISK A/S (DK) | 2017-09-14 | — | — | US | disclosed |
| US-20160311934-A1 | HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2016-10-27 | — | — | US | disclosed |
| WO-2016042093-A1 | ANTIBODIES CAPABLE OF BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR (1-161) | NOVO NORDISK A/S (DK) | 2016-03-24 | — | — | WO | disclosed |
| US-20160032012-A1 | ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR | NOVO NORDISK A/S (DK) | 2016-02-04 | — | — | US | disclosed |
| WO-2014147173-A1 | HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147175-A1 | HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014140240-A1 | ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR | NOVO NORDISK A/S (DK) | 2014-09-18 | — | — | WO | disclosed |
| US-8158746-B2 | Active energy ray curable liquid composition and liquid cartridge | CANON KABUSHIKI KAISHA (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20100324163-A1 | ACTIVE ENERGY RAY CURABLE LIQUID COMPOSITION AND LIQUID CARTRIDGE | CANON KABUSHIKI KAISHA (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311934-A1 | HYDROXYALKYL STARCH DERIVATIVES AS REACTANTS FOR COUPLING TO THIOL GROUPS | MSR1, C3AR1, C1R | MGLL 559/4885CA2 3075/4885CA12 1251/4885 |
| US-20160032012-A1 | ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR | TFPI, TFPI2, F13B | MGLL 3996/4885CA2 2007/4885CA12 1279/4885 |
| US-20230322958-A1 | Anti-Notch2 Antibodies and Conjugates and Methods of Use | NOTCH2, NOTCH3, NOTCH4 | MGLL 3940/4885CA2 2300/4885CA12 59/4885 |
| US-20170260289-A1 | ANTIBODIES CAPABLE OF BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR (1-161) | TFPI, TFPI2, F13B | MGLL 4171/4885CA2 2207/4885CA12 1164/4885 |
| US-20180208675-A1 | ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR | TFPI, TFPI2, F13B | MGLL 3996/4885CA2 2007/4885CA12 1279/4885 |
| US-10717784-B2 | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor | TFPI, TFPI2, F13B | MGLL 3996/4885CA2 2007/4885CA12 1279/4885 |
| US-11279771-B2 | Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) | TFPI, TFPI2, F13B | MGLL 4171/4885CA2 2207/4885CA12 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.